Interview with Aiden Flynn from Exploristics
Aiden has first worked on simulations during studying statistics to understand which sample sizes lead to sufficient performance of statistics, which are only asymptotically normal. It helped him in many situations, in which it was difficult to tackle a problem analytically. Simulations help us understand very complex situations, and the development of new treatments is surely a very complex topic.
He has invested an enormous amount of time to leverage simulations for understanding the designs of studies and development programs. In this episode, I discuss the following questions with him:
- Why is trial simulation necessary?
- What design features do you assess?
- How do you get a good stability in terms of the simulation precision?
- Where are the limitations to these simulations?
- What are his experiences in communicating the outcomes of the simulation?
- How he thinks simulating studies or development programs will look like in 5 years?
Listen to this episode while we answer these six important questions.
Aiden Flynn, BSc MSc PhD
Chief Executive Officer
Aiden is the founder of Exploristics and has over 20 years’ experience in the life sciences sector. After seven years as a researcher and lecturer at University College London, Aiden spent ten years at GlaxoSmithKline as a director of statistical support for biomarker studies across research and development. Here, he was responsible for developing and implementing the pharmacogenetics strategy that enabled the use of genetic data in clinical studies. This involved the integration of a wide range of capabilities across R&D such as new analysis tools and methods, bioinformatics, data standards, processes and training.
In recent years, Aiden has worked closely with regulatory authorities, such as the FDA and EMA, to develop tools and guidelines that support the use of biomarkers in clinical studies. Since founding Exploristics in 2009, Aiden has overseen its growth, creating an innovative and profitable company able to cater to a wide range of healthcare developers from the world’s top pharmaceutical companies to biotechnology, medical device and diagnostic start-ups.
Listen and share this episode with your friends and colleagues!